MARKET

TNYA

TNYA

Tenaya Therapeutics, Inc.
NASDAQ
0.8081
+0.0206
+2.62%
After Hours: 0.8155 +0.0074 +0.92% 19:44 05/20 EDT
OPEN
0.8100
PREV CLOSE
0.7875
HIGH
0.8242
LOW
0.7900
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
2.350
52 WEEK LOW
0.3901
MARKET CAP
175.36M
P/E (TTM)
-1.7153
1D
5D
1M
3M
1Y
5Y
1D
Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX) and Tenaya Therapeutics (TNYA)
TipRanks · 2d ago
Weekly Report: what happened at TNYA last week (0511-0515)?
Weekly Report · 2d ago
Buy Rating Reiterated on Tenaya: Promising TN-401 RIDGE-1 Data, Strong Transgene Expression, and Upcoming Catalysts Support Attractive Risk/Reward
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)
TipRanks · 5d ago
Analyst Reiterates Buy on Positive TN-401 RIDGE-1 Data Despite Cutting Price Target from $19 to $3
TipRanks · 5d ago
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
Benzinga · 5d ago
Tenaya Shares Rise on Positive Data From ARVC Study
Dow Jones · 5d ago
More
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Webull offers Tenaya Therapeutics Inc stock information, including NASDAQ: TNYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNYA stock methods without spending real money on the virtual paper trading platform.